Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1659-1665

  Cao, Li Ping ^a   Song, Jian Lin ^a   Yi, Xiao Ping ^b   Li, Yi Xiong ^a  

^a Departments of General Surgery   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chemoresistance; Gemcitabine; Nuclear factor B; Pancreatic cancer; RNAi; X linked inhibitor of apoptosis protein

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; P65 SIRNA; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; XIAP SIRNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL LINE; CELL STRAIN MIA PACA2; CELL STRAIN PANC 1; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE CONTROL; GENE SILENCING; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; RNA INTERFERENCE;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84874688230     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2246     Document Type: Article

References (34)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Tempero MA, Arnoletti JP, Behrman SW, et al: Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw 10: 703-713, 2012.
3. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518, 2009.
4. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
5. Raguz S and Yague E: Resistance to chemotherapy: new treat¬ments and novel insights into an old problem. Br J Cancer 99: 387-391, 2008.
6. Arlt A, Muerkoster SS and Schafer H: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett: November 13, 2010. doi: 10.1016/j.canlet.2010. 10.015.
7. Wan F and Lenardo MJ: The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res 20: 24-33, 2010.
8. Sebens S, Arlt A and Schafer H: NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res 177: 151-164, 2008.
9. Kanarek N, London N, Schueler-Furman O and Ben-Neriah Y: Ubiquitination and degradation of the inhibitors of NF-kappaB. Cold Spring Harb Perspect Biol 2: a000166, 2010.
10. Biswas DK, Martin KJ, McAlister C, et al: Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res 63: 290-295, 2003.
11. Gyrd-Hansen M and Meier P: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10: 561-574, 2010.
12. Eckelman BP, Salvesen GS and Scott FL: Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7: 988-994, 2006.
13. Chandler NM, Canete JJ and Callery MP: Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res 118: 9-14, 2004.
14. Weichert W, Boehm M, Gekeler V, et al: High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 97: 523-530, 2007.
15. Arlt A, Gehrz A, Muerkoster S, et al: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251, 2003.
16. Kong R, Sun B, Jiang H, et al: Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. Cancer Lett 291: 90-98, 2010.
17. Pan X, Arumugam T, Yamamoto T, et al: Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 14: 8143-8151, 2008.
18. Kashkar H: X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res 16: 4496-4502, 2010.
19. Shrikhande SV, Kleeff J, Kayed H, et al: Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res 26: 3265-3273, 2006.
20. Lopes RB, Gangeswaran R, McNeish IA, Wang Y and Lemoine NR: Expression of the IAP protein family is dysregu¬lated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 120: 2344-2352, 2007.
21. Li Y, Jian Z, Xia K, et al: XIAP is related to the chemoresis¬tance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 32: 288-296, 2006.
22. Fan Y, Dutta J, Gupta N, Fan G and Gelinas C: Regulation of programmed cell death by NF-kappaB and its role in tumorigen-esis and therapy. Adv Exp Med Biol 615: 223-250, 2008.
23. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G and Schmid RM: Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 105: 735-746, 2003.
24. Trauzold A, Schmiedel S, Roder C, et al: Multiple and syner¬gistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer 89: 1714-1721, 2003.
25. + inhibits cancer cell growth through inactivation of NF-?B and STAT3 signals. Oncogene 30: 3345-3359, 2011.
26. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69: 195-206, 2006.
27. Manna SK, Aggarwal RS, Sethi G, Aggarwal BB and Ramesh GT: Morin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and inflammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expression and up-regulation of apoptosis. Clin Cancer Res 13: 2290-2297, 2007.
28. Moon DO, Kim MO, Lee JD and Kim GY: Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells. Cancer Lett 264: 192-200, 2008.
29. Hannon GJ: RNA interference. Nature 418: 244-251, 2002.
30. Bilim V, Yuuki K, Itoi T, et al: Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer 98: 941-949, 2008.
31. Kunze D, Wuttig D, Fuessel S, et al: Multitarget siRNA inhibi¬tion of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res 28: 2259-2263, 2008.
32. Ruckert F, Samm N, Lehner AK, Saeger HD, Grutzmann R and Pilarsky C: Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. BMC Cancer 10: 379, 2010.
33. Liston P, Fong WG and Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22: 8568-8580, 2003.
34. Seeger JM, Brinkmann K, Yazdanpanah B, et al: Elevated XIAP expression alone does not confer chemoresistance. Br J Cancer 102: 1717-1723, 2010.